Gas chromatography-mass spectrometric method-based urine metabolomic profile of rats with pelvic inflammatory disease

Introduction

Pelvic inflammatory disease (PID) is a common disorder induced by ascending infection of the upper female genital tract by, for example, Neisseria gonorrhoeae, Chlamydia trachomatis, genital mycoplasmas, gram-negative bacteria or gram-positive bacteria (1–4), the symptoms of which include endometritis, salpingitis and peritonitis (5). This disease is considered to be a great threaten to women as it can lead to a poor outcome with severe sequelae, such as tubal factor infertility, ectopic pregnancy and chronic pelvic pain. The diagnosis of PID is dependent upon evaluation of the patient's history, physical examination, laboratory studies and imaging (5). However, the sensitivity and specificity of clinical diagnosis have been reported to be only 87 and 50%, respectively (6). Although laparoscopy is the gold standard for diagnosis, its routine use is limited by poor compliance (7). Therefore, a novel and non-invasive method is necessary for clinical diagnosis of PID.

Metabolomics, a key technology for the evaluation of system biology, focuses on the comprehensive qualification and quantification of all endogenous metabolites of low molecular mass in vivo, and thus reveals the pathological and physiological changes of the whole biosystem from the aspect of metabolism (8,9). Metabolomics has been carried out to identify disease-related metabolites as biomarkers that contribute to the non-invasive diagnosis of diseases. A previous study has found that 3-hydroxybutyrate, N-acetyl-glycine, 3-hydroxy-2-methyl-butanoic acid and nonanedioic acid in the plasma can serve as biomarkers for the diagnosis of breast cancer (10). The levels of sarcosine in urine can contribute to the diagnosis of prostate cancer (11), and desmosterol in plasma has been identified as a new specific biomarker of Alzheimer's disease (12). However, to the best of our knowledge, no metabolomic study has yet been carried out to search for novel metabolite biomarkers of PID.

Gas chromatography coupled with mass spectrometry (GC/MS) is one of the core analytical methods for metabolomic study and has been used as a platform in non-targeted metabolomic analysis (13,14). Through GC-MS analysis, the chemical structure of metabolites can be inferred by comparing the mass spectrometric fragmentation pattern with mass spectral libraries, which facilitates the identification of biomarkers. Silylation is a common method of derivatization, the application of which in GC-MS analysis can enable the detection of more metabolites, including carbohydrates, amino acids and nucleosides (15).

Following renal concentration, urine amplifies the circulating levels of metabolites and thus exhibits metabolomic alterations more clearly. In addition, urine collection is non-invasive. Hence, urine is of interest in metabolomic research. In the majority of medical research, animal experiments are usually carried out first to estimate the importance of conducting clinical experiments and offer valuable information. Therefore, on the basis of silylation and GC-MS analysis, the present urine non-targeted metabolomic study was carried out in a rat model of PID to illustrate the metabolic alterations associated with PID, and identify the potential biomarkers of PID accordingly.

Materials and methods

Reagents and materials

Ultrapure water was produced using a Milli-Q Plus Water Purification System (EMD Millipore, Milford, MA, USA). Pentobarbital was purchased from Xiya Reagent Co., Ltd. (Chengdu, China). Progesterone injection was obtained from Zhejiang Xianju Pharmaceutical Co., Ltd. (Taizhou, China). N,O-Bis(trimethylsilyl)-trifluoro-acetamide-trimethylchlorosilane (BSTFA-TMCS) (99:1, v/v), urease, margaric acid, tropic acid, methoxylamine hydrochloride, pyridine and metabolite standards were purchased from Sigma-Aldrich (St. Louis, MO, USA). Absorbable gelatin sponge was purchased from Jinling Pharmaceutical Co., Ltd. (Nanjing, China).

PID model construction and sample collection

The experimental procedures were approved by the Animal Care and Use Committee of Central South University (Changsha, China). The harm to animals was minimized with the greatest efforts. Sixteen female specific pathogen-free Sprague Dawley (SD) rats, aged 9 weeks and weighing 210–230 g, were purchased from Silaikejingda Experimental Animal Co., Ltd. (Changsha, China). They were randomly divided into two groups, namely the control group and the PID group. Standard laboratory chow was available ad libitum through the whole experiment. All the rats were acclimated for a week and then injected subcutaneously with 10 mg progesterone 7 days prior to experimentation. PID modeling was conducted with reference to a previous method (16,17). Ureaplasma urealyticum (t-strain mycoplasma) and a pathogenic Escherichia coli strain (No. 0573) were obtained from Clinical Laboratory Department of the Maternal and Child Health Hospital of Hunan Province (Changsha, China). An absorbable gelatin sponge, with a volume of 0.125 ml, was immerged into a microbe-mixing solution with a U. urealyticum concentration of 1×108 ccu/ml and E. coli concentration of 1×108 cfu/ml. Then, the cervix of each rat in the PID group was implanted with the microbe-containing gelatin sponge, and the rat was positioned upside down for 3 min. The cervixes of control group rats were implanted with gelatin sponges immerged in saline. This infection procedure was conducted once every 2 days and repeated four times. Surface disinfection was carried out with 70% alcohol following each infection. On the 21st day from the first infection, a 24 h urine sample of each rat was collected and stored at −80°C. Then, vaginal swab samples from rats were obtained to detect U. urealyticum, and E. coli using a mycoplasma detection kit and TDR-300B automatic microbial analysis system (Tiandiren Biotech Co., Ltd., Changsha, China), respectively. After that, rats were anesthetized with pentobarbital (dose, 30 mg/kg). Plasma and the right uterus and fallopian tube were collected and stored at −80°C, and the left uterus and fallopian tube were used for histological examination. Then, all the rats were sacrificed via cervical dislocation.

Histological examination

The left uterus and fallopian tube of each rat were fixed in neutral-buffered formalin (10%), embedded in paraffin, cut into 2-µm sections, and stained with hematoxylin and eosin (H&E). Three different fields for each tissue sample were examined using light microscopy (DM500l; Leica Microsystems GmbH, Wetzlar, Germany) at a magnification of ×100 by a blinded observer. The inflammation of the uterus and fallopian tube of each animal was semi-scored by the observer's evaluation of the degree of inflammatory cell infiltration (graded from 0 to 3) for each of the three fields.

C-reactive protein (CRP), interleukin (IL)-1β and IL-6 determinations

The concentration of CRP in plasma was measured using enzyme-linked immunosorbent assay (ELISA) kits (RayBiotech, Norcross, GA, USA). The right upper genital tract (including uterus and fallopian tube) of each rat was weighed, followed by the addition of physiological saline at the ratio of 5:1 (v/w) and homogenization. The total protein of the homogenate was measured using a bicinchoninic acid assay kit (Beyotime Institute of Biotechnology, Shanghai, China). The concentrations of IL-1β and IL-6 in the homogenate were determined using the ELISA kits and presented in units of µg/g protein of homogenate. These procedures were performed according to the protocols of the manufacturers.

Urine sample preparation

Thawed urine samples were diluted to give a creatinine concentration of 2.5 mmol/l as determined using a JEOL JCA-BM1650 clinical biochemistry analyzer (JEOL Ltd., Tokyo, Japan). A 30-unit quantity of urease was added to 100 µl urine and the mixture was incubated for 30 min at 37°C. Then, 50 µl of a mixed solution of margaric acid and tropic acid, each of concentration 0.5 mg/ml, was added as an internal standard. An aliquot of 800 µl ethanol was mixed with the sample, and then the mixture was centrifuged at 12,000 × g for 15 min. The supernatant was transferred to a new tube and stored at −20°C for 10 min. After drying the supernatant in a vacuum dryer at room temperature, 100 µl methoxylamine hydrochloride (20 mg/ml in pyridine) was added with mixing, and the resultant mixture was incubated at 37°C for 2 h. Then, 100 µl BSTFA-TMCS was added and the mixture was heated to 70°C for 1 h. A quality control (QC) sample was prepared by mixing urine from each rat and handling according to the above protocol.

GC-MS analysis

GC-MS analysis was undertaken on an Agilent 7890 gas chromatography system equipped with an Agilent 5975C mass analyzer (Agilent Technologies, Inc., Palo Alto, CA, USA). Separation was conducted on an Agilent DB-5MS capillary column (30 m × 0.25 mm internal diameter × 0.25 µm film thickness). Each 1 µl aliquot of the derivatized solution or reference standard was injected in the splitless mode and helium was used as the carrier gas with flow rate of 1.5 ml/min. The temperatures of the inlet, transfer line and ion source were maintained at 250, 300 and 230°C, respectively. The GC temperature programming was set to 4 min isothermal heating at 60°C, followed by the first ramp at 6°C/min to 150°C and holding for 8 min, second ramp at 8°C/min to 280°C and holding for 10 min, and third ramp at 12°C/min to 320°C. Data acquisition was achieved using MS in the electron impact mode at 70 eV and in the full-scan monitoring mode with a mass to charge (m/z) ratio from 35 to 750. The chromatogram acquisition and detection of mass spectral peaks were performed using G1701EA GC/MD ChemStation software (Agilent Technologies, Inc.).

Data analysis and potential biomarker identification

The peak areas of metabolites in each sample were normalized to the peak area of creatinine. Internal standards were used to calibrate the retention time of all metabolites and monitor sampling and instrumental condition. Then, a data set of all samples, consisting of the retention time and the normalized peak area of metabolites, was generated and imported into SIMCA-P software (version 11.5; Umetrics; MKS Instruments, Umeå, Sweden) for multivariate analysis. The data were processed by unit variance scaling and were mean-centered, followed by multivariate analysis including principal component analysis (PCA) and partial least squares discriminant analysis (PLS-DA) between the PID group and control group. The unsupervised statistical analysis PCA was used to describe associations and patterns among a set of variables; R2X and Q2 are two measures of PCA model quality. Metabolites relevant for group discrimination were selected by the values of variable importance in the projections (VIP) >1 constructed from PLS-DA analysis. The Student's t-test was employed for the metabolites with VIP>1, and the differentiating metabolites were selected when P<0.05 with the Benjamini and Hochberg procedure to control the false discovery rate (FDR) (18). The mass fragmentation patterns of these potential biomarkers were compared with the NIST/EPA/NIH Mass Spectral Library 2011 (version NIST11; Gaithersburg, MD, USA) to predict their chemical structures. The further identification of these differentiating metabolites was performed by comparing their mass spectra and chromatographic retention times to those of standards.

Statistical analysis

Data are presented as mean ± standard deviation (SD). Statistical analysis was performed by unpaired Student's t-test using SPSS for Windows 16.0 (SPSS, Inc., Chicago, IL, USA). P<0.05 was considered to indicate a statistically significant result.

Results

PID model construction

The vaginal swab samples of rats from the PID group tested positive for both U. urealyticum and E. coli, whereas the control rats tested negative for the two pathogens. These results indicated that infection in the PID group rats was successfully achieved. Histological examination revealed that, in comparison with control rats, upper genital tract infection with these pathogens caused significant inflammation, of the uterus and the fallopian tubes (Fig. 1A–D), including mass neutrophil and lymphocyte infiltration. Semi-quantitative scoring of the inflammation of the uterus (Fig. 1E) and fallopian tubes (Fig. 1F) showed a significant difference between the PID and control groups. The CRP levels in plasma, and expression levels of IL-1β and IL-6 in the upper genital tract (including the uterus and fallopian tube) were significantly higher in PID model rats, as compared with the control animals (Fig. 2), which indicated that an inflammatory response occurred in upper genital tract.

Figure 1. Histological changes of the uterus and fallopian tube after pathogenic infection. Representative micrographs of uterus and fallopian tube stained with hematoxylin and eosin (magnification, ×100) are shown. Uterus of (A) a control rat and (B) a PID rat, and fallopian tube of (C) a control rat and (D) a PID rat. Lymphocyte cell infiltration is indicated with ▲, and positive staining of neutrophils is indicated with ↑. Histological semi-quantitative scores of inflammatory cell infiltration in the (E) uterus and (F) fallopian tube are presented. Each bar represents the mean ± standard deviation. *P<0.01 vs. the control group, n=3). PID, pelvic inflammatory disease.

Figure 2. Expression changes of (A) CRP in the plasma and (B) IL-1β and (C) IL-6 in the upper genital tract (including uterus and fallopian tube) following pathogenic infection. Each bar represents the mean ± standard deviation. *P<0.01 vs. the control group, n=8). CRP, C-reactive protein; IL, interleukin; PID, pelvic inflammatory disease.

Assessment of the repeatability and stability of the analytical method

A representative chromatogram for the GC-MS coupled with derivatization method is shown in Fig. 3. Repeatability and stability of the analytical method are essential for obtaining valid metabolomic data. In the present study, a stability test was performed by analyzing 6 injections of a QC sample, and the relative standard deviations (RSDs) of eight common ions were <0.27% for retention times and <5.35% for peak areas. The repeatability was evaluated by the analysis of 6 QC samples, with the RSDs of peak area <11.28%. These results validated the analytical method for metabolite determination.

Figure 3. Representative base peak intensity chromatogram of rat urine obtained by gas chromatography-mass spectrometry coupled with a derivatization method.

Multivariate statistical analysis

A three-component PCA model was selected to reveal the general metabolic differences between groups, with R2X=0.751 and Q2=0.412. As presented in Fig. 4A, the PID group was clearly separated from the control group. Subsequently, a PLS-DA was employed to further elucidate the metabolic differentiation associated with PID. A clear separation is shown in Fig. 4B, with three predictive components and three orthogonal components (R2X=0.652, R2Y=0.934, Q2=0.720). These results indicated that the metabolic profile of rats was evidently disturbed by PID.

Figure 4. Rats in the PID group exhibited a distinct metabolic profile from the control rats. (A) PCA 3-D scores and (B) PLS-DA 3-D scores plots, based on the metabolomic data obtained from urine. The gray data points indicate control rats, and the black data points indicate PID rats. PID, pelvic inflammatory disease; PCA, principal component analysis; DA, discriminant analysis.

Potential biomarker identification

Eighteen differentiating metabolites were selected as potential biomarkers with VIP>1 and P<0.05, followed by the identification of chemical structures using commercial standards. Typical mass spectra of phenylalanine in urine and phenylalanine standard are presented in Fig. 5. A heat map of the potential biomarkers is presented in Fig. 6, which visualizes the fold level changes between the rats in the PID and control groups. These differentiating metabolites are four amino acids, three fatty acids, nine organic acids and two sugars. The levels of 14 metabolites were notably increased in the urine of the rats with PID compared with their levels in control rats, but the levels of four metabolites, namely glycine, glucose, galactose and arachidonate, were decreased.

Figure 5. Representative mass spectrum of (A) phenylalanine in rat urine and (B) phenylalanine standard. m/z, mass to charge ratio.

Figure 6. Heat map showing the unsupervised hierarchical clustering of 18 differentiating metabolites across the control and PID groups. The PID group and control group are indicated by black and gray bars, respectively. The columns represent the individual rats, and the rows indicate differentiating metabolites. Increases in the intensities of red and blue indicate elevations and decreases, respectively, in the levels of a metabolite relative to the median metabolite production. *P<0.01 vs. the control group, n=8. PID, pelvic inflammatory disease.

Discussion

To the best of our knowledge, no previous study has delineated the metabolomic changes that are associated with PID. The aim of the present study was to examine the PID-associated disturbance of metabolism in rats with the further aim of identifying potential metabolite biomarkers for use in the diagnosis of this disease.

Toll-like receptors (TLRs) play a key role in evoking the inflammatory response to microbial infection in the genital tract (19). U. urealyticum (20) can be recognized by TLR 2, and pathogenic E. coli (21) causes an inflammatory response through TLR 4. Furthermore, both U. urealyticum and E. coli are common pathogens of PID (22). Therefore, to activate multiple TLRs and induce a quick and enhanced inflammatory response in the genital tract, a solution containing a mixture of U. urealyticum and E. coli was used to construct a PID rat model, as in previous studies (16,17). Following infection, mass neutrophil and lymphocyte infiltrations indicated inflammation in the uterus and fallopian tube (Fig. 1). The elevation of CRP levels in plasma has been used to differentiate inflammatory from non-inflammatory pelvic pathology in vivo (23). CRP examination has been included in the criteria for the diagnosis of PID proposed in the USA (24). In the PID model in the present study, the elevated CRP levels in plasma (Fig. 2A) illustrated the inflammatory response. The pro-inflammatory cytokine IL-1β is a key factor in the pathological development of PID (25), and the cytokine IL-6 is involved in the processes of chronization and suppression of the synthesis of IL-1β in the second phase of the immune response (26). Both IL-1β and IL-6 exhibit significant elevation in patients with PID (27). Hence, as shown in Fig. 2B and C, the elevated expression of IL-1β and IL-6 in the uterus and fallopian tube validated the local inflammatory response in the rat PID model.

The biochemical reactions associated with the differentiating metabolites can be determined using the Kyoto Encyclopedia of Genes and Genomes (KEGG; http://www.genome.jp/kegg/) and the Human Metabolome Database (HMDB, http://www.hmdb.ca/). The present study illustrated that the comprehensive metabolic profile changes associated with PID in rats are associated with sugar metabolism, the citric acid cycle (TCA cycle), amino acid metabolism and fat acid metabolism. The concurrence of reductions in the levels of sugars (glucose and galactose) and an increase in pyruvate levels indicated enhanced glycolysis in PID rats. In addition, the upregulation of citrate suppresses citrate synthase activity, followed by increased lactate production from pyruvate. The elevated levels of intermediate products in the TCA cycle, including citrate, aconitate, succinate and malate, suggest possible defects in the mitochondrial respiratory system, and the concentration changes of alanine, glycine, phenylalanine and proline indicate alterations of amino acid metabolism. The increase of glutarate and adipate in PID rats illustrates an abnormality of fat acid metabolism that is also present in arthritis (28,29). Leukotriene B4 (LTB4) is able to promote leucocyte recruitment (30), and increased prostaglandin E2 (PGE2) levels lead to edema and a hyperalgesic response (31). The overproduction of both in women with PID (32) may be involved in modulation of the inflammatory response. As arachidonate is the primary precursor of LTB4 and PGE2, high levels of production of LTB4 and PGE2 will consume considerable arachidonate. Consistently, a reduction in the levels of arachidonate was observed in the rats with PID in the present study. The elevation of citraconate also occurs in experimental arthritis (29), indicating a modulation of branched pentadioic acid metabolism relating to an inflammatory response. 2-Hydroxybutyrate is a by-product of ophthalmate synthesis, a high level of which indicates glutathione depletion (33). The increased levels 2-hydroxybutyrate observed in rats with PID in this study may suggest a shortage of glutathione and oxidative stress in the genital tract, which is also observed in endometriosis (34). Acetic acid is a substance existing as an antibacterial agent in the vaginal lubrication fluid of humans (35). Notably, elevated pyruvate levels may have promoted acetate production in the present study, as pyruvate can be metabolized by pyruvate dehydrogenase to produce acetate (36). This elevation of acetate levels may be considered as a physiological response to defend against the following infection.

In conclusion, a PID model was constructed by multi-pathogenic infection of the upper genital tract in rats. Infiltration of inflammatory cells and elevated expression levels of cytokines in the uterus and fallopian tube validated the disease model. The results reveal PID-associated metabolomic changes in the rat PID model. Eighteen differentiating metabolites were found, which are associated with sugar metabolism, the TCA cycle, amino acid metabolism and fatty acid metabolism. These metabolites could be potential biomarkers of PID. This study also offers a new approach to evaluate the effect of anti-PID drugs in pre-clinical or clinical trials.

Acknowledgements

The authors thank the Clinical Laboratory Department and Department of Pathology in the Maternal and Child Health Hospital of Hunan Province for experimental support. The present study was supported by the National Natural Science Foundation of China (grant no. 81501218), China Postdoctoral Science Foundation (grant no. 2015M582330), Science and Technology Project of Hunan Province (grant no. 2015RS4054) and Administration of Traditional Chinese Medicine of Hunan Province (grant no. 201402).

Glossary

Abbreviations

Abbreviations:

References